Generics· June 27, 2026 · 18 min read
Generic Restasis: Complex Ophthalmic Barriers and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Ophthalmology
Topic
Ophthalmology
Intravitreal injections, retinal vascular disease, anti-VEGF therapy, ophthalmology biosimilars, and site-of-care access.
Pricing & Access· May 31, 2026 · 13 min read
Retina buy-and-bill inventory risk when payer preference changes
By Ran Chen#Anti-VEGF#Ophthalmology#Buy and Bill
Pipeline· May 31, 2026 · 10 min read
Veligrotug vs Tepezza thyroid eye disease access guide
By Ran Chen#PDUFA Date#FDA Approval#Ophthalmology
Pricing & Access· May 27, 2026 · 13 min read
Eylea HD vs Vabysmo access comparison for retina practices
Biosimilars· May 27, 2026 · 9 min read
Lucentis biosimilars access guide for retina practices
By Ran Chen#Biosimilars#Anti-VEGF#Ophthalmology
Pricing & Access· May 27, 2026 · 11 min read
Syfovre vs Izervay geographic atrophy access guide
Pricing & Access· May 27, 2026 · 11 min read
Tepezza coverage guide for thyroid eye disease access
Pricing & Access· May 27, 2026 · 10 min read
Vabysmo coverage guide for retina access
Biosimilars· May 21, 2026 · 8 min read